Corporate News

GOLDMAG was successfully selected

One of the top 500 enterprises in the "Maker China" National enterprise Group

Gold medal quality magnetic protection for health

Recently, the list of the top 500 enterprises in the national enterprise group of the 10th "Maker China" Small and Medium-sized Enterprises Innovation and Entrepreneurship Competition was officially announced. Xi 'an Jinci Nano Biotechnology Co., Ltd. stood out among many outstanding enterprises across the country with its innovative project "Research and Development and Clinical Application of New Pan-Vascular Disease Marker Detection Kits" and was successfully selected, fully demonstrating the company's solid strength and innovative potential in the field of biomedical testing.

As a national authoritative event jointly hosted by the Ministry of Industry and Information Technology and the Ministry of Finance, "Maker China" is an important platform for showcasing the innovation achievements of small and medium-sized enterprises, with its influence covering the entire country. A total of 34 regional competitions, 16 thematic competitions and 1 overseas event were held in this competition, making it highly competitive. After several rounds of strict review and public announcement, the final list of the top 500 was determined. The selected enterprises are all innovation benchmarks in their respective fields, and their "gold content" and "intelligence content" are highly recognized by the industry. The inclusion of Jinci Biology is not only a high recognition of the technical value of the project by the competition, but also an authoritative endorsement of the company's innovation capabilities by the industry.

Jinci Biotechnology has always been dedicated to the research and development as well as the transformation of nanobiotechnologies and in vitro diagnostic reagents. The selected projects this time focus on the clinical difficulties in the early diagnosis of pan-vascular diseases. Relying on the high-performance nano-biosensing technology platform independently built by the company, they have achieved highly sensitive and specific detection of key disease markers, effectively improving the accuracy of early screening and risk assessment, and have significant clinical value and application prospects.

This selection into the national top 500 is a concentrated demonstration of the competitiveness of Jinci Biotech's R&D and innovation system, and it also injects strong impetus into the subsequent clinical promotion and industrialization of the project. In the future, the company will continue to take innovation as the engine, deepen technological research and development, accelerate the transformation of achievements, and serve precision medicine with more competitive diagnostic products, contributing the "Golden Magnetic power" to improving the health level of the entire population.